ASCO 2020 | DUTRENEO: durvalumab and tremelimumab vs chemo

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, highlights data coming from the DUTRENEO trial. This randomized phase II trial evaluated DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach in patients with muscle-invasive urothelial bladder cancer who were prospectively selected by an interferon-gamma immune signature. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).